Nuwellis (NASDAQ:NUWE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Nuwellis (NASDAQ:NUWE) announced its earnings results on Tuesday. The company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.56) by $0.06, FiscalAI reports. Nuwellis had a negative net margin of 202.83% and a negative return on equity of 1,367.63%. The firm had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.31 million.

Here are the key takeaways from Nuwellis’ conference call:

• Company completed a transition to contract manufacturing with KDI Precision Manufacturing to improve supply reliability and long-term structural margins, prioritizing operational predictability over short-term cost cuts.
• Strategic refocus on the cardiorenal continuum—with emphasis on heart failure and pediatrics—was reinforced by expanded IP and a NIH grant supporting the pediatric device (Vivian), strengthening long-term differentiation.
• Management is integrating the Rendiatech acquisition (Clarity) to add bedside urine-output and analyte monitoring for ICU/critical-care patients, with a planned mid-year relaunch to drive deeper utilization in existing accounts.
• Financials show mixed trends: Q4 revenue rose to $2.4M and gross margin improved, but full-year revenue fell 5%, net loss was $17.5M (including a $6.4M non-cash warrant expense), and year-end cash was only about $1.2M after ~$10.9M cash usage.
• Commercially, U.S. console sales jumped 208% in Q4 and the direct sales team is now 24 people focused on driving utilization in existing accounts (particularly critical care), with headcount expected to remain stable in 2026.

Nuwellis Stock Up 3.5%

Shares of NASDAQ NUWE traded up $0.05 during mid-day trading on Tuesday, reaching $1.34. 178,569 shares of the company were exchanged, compared to its average volume of 2,830,714. Nuwellis has a twelve month low of $1.20 and a twelve month high of $53.34. The company’s 50-day simple moving average is $2.17 and its 200-day simple moving average is $2.87. The stock has a market capitalization of $2.50 million, a P/E ratio of -0.01 and a beta of -0.03.

Analyst Upgrades and Downgrades

NUWE has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, December 29th. Wall Street Zen lowered shares of Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.